🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07473921
Starting soon Not applicable

Supracrestal Socket Shield Technique in Anterior Maxilla. A Case Series

NCT07473921 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-09-01
Last updated
2026-07-01

Condition(s) studied

Immediate Dental Implant PlacementAnterior Maxilla

Investigational drug(s) / intervention(s)

Supracrestal SST

Supracrestal SST: Supracrestal Socket Shield Technique (SSST) 1\. Concept and Biological Principle The technique is based on partial extraction therapy. Normally, after extraction: The periodontal ligament (PDL) is lost The bundle bone of the buccal plate resorbs This leads to buccal bone collapse and gingival recession In SSST: The buccal root fragment is preserved The PDL and vascular supply remain intact The bundle bone does not resorb This maintains ridge contour and papilla stability The supracrestal extension (≈0.5-1 mm above bone crest) helps: Maintain soft tissue support Improve emergence profile Reduce mid-facial recession

Study summary

Post-extraction labio-palatal ridge collapse is a significant challenge in restorative and implant dentistry particularly in anterior maxilla. Following tooth extraction, marked dimensional alveolar ridge changes occur. The buccal plate of bone in the anterior zone is primarily composed of bundle bone, a tooth dependent structure that derives its blood supply from the periodontal ligament (PDL). The PDL loss after tooth extraction results in rapid resorption of the bundle bone, leading to horizontal and vertical ridge reduction (Araújo and Lindhe, 2005, Schropp et al., 2003). Studies have shown that 50% of ridge width reduction occurs within 12 months, with two thirds of this reduction occurring within the first 3 months (Schropp et al., 2003). Moreover, the labial plate thickness in the anterior maxilla is frequently thinner than 1 mm in the majority of cases (Huynh-Ba et al., 2010). The high incidence of mid-facial recession and soft tissue volume loss is attributed to those biological events.

Although IIP has become increasingly popular due to its short treatment time, it doesn't prevent physiological remodeling associated with bundle bone resorption (Araújo and Lindhe, 2005). Consequently, soft tissue collapse and midfacial recession remain common complications, especially in thin periodontal phenotypes (Chappuis et al., 2013, Cosyn et al., 2012). In order to overcome the inevitable consequences of tooth extraction, a variety of ridge preservation techniques were proposed in the literature including; flapless implant placement, bone grafting, soft tissue augmentation procedures, immediate provisionalization, a more palatal orientation of the implant in the socket and the socket shield technique.

Eligibility

Sex
ALL
Min age
21 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients who have a single bounded non-restorable maxillary anterior tooth with opposing natural dentition with no periapical pathosis. * Adults above the age of 21. * Good oral hygiene. * Patient accepts to provide informed consent. * Thin intact labial plate of bone (1 mm or less), assessed by CBCT. * Intact gingival tissue with at least 2 mm keratinized tissue. * Teeth with intact labial root surfaces. * Minimum of 3-4 mm of apical bone for primary stability Exclusion Criteria: • Smokers. * Pregnant and lactating females. * Medically compromised patients. * Patients with untreated active periodontal diseases. * Patients with active infection related to the implant site

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
International dental continuing education Cairo Cairo Governorate

More International Dental Contiuing Education trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07473921 on ClinicalTrials.gov ↗ ← All trials in Egypt